Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

BACKGROUND: BG-12 (dimethyl fumarate) was shown to have antiinflammatory and cytoprotective properties in preclinical experiments and to result in significant reductions in disease activity on magnetic resonance imaging (MRI) in a phase 2, placebo-controlled study involving patients with relapsing-r... View More